search
Back to results

Efficacy and Safety of Dexketoprofen/Vitamin B vs Dexketoprofen for Post-traumatic Cervical Sprain Grade I-II (WHIPLASH)

Primary Purpose

Acute Low Back Pain

Status
Completed
Phase
Phase 3
Locations
Mexico
Study Type
Interventional
Intervention
Dexketoprofen/Vitamin B
Dexketoprofen
Sponsored by
Laboratorios Silanes S.A. de C.V.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Low Back Pain

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Any sex.
  • That the subject agree to participate in the study and give your written informed consent.
  • Age> 18 years old at the beginning of the study.
  • Diagnosis of a grade I or Grade II cervical sprain on the Quebec scale of no more than 3 days.
  • Visual Analog Scale (VAS) ≥4 cm.
  • Women of childbearing potential using a contraceptive method (barrier, oral hormonal, injectable, subdermal), menopausal or surgically sterile.

Exclusion Criteria:

  • Patient in whom the drug is contraindicated for medical reasons.
  • History of allergic reaction to NSAIDs, thiamine, pyridoxine and cyanocobalamin or hypersensitivity to the components of the formula.
  • A significant history of gastrointestinal disorders (for example: Gastric Ulcer, Crohn's Disease, Ulcerative Colitis, etc.)
  • Previous treatment with opioids reported in the medical history.
  • History of inflammatory arthritis (eg rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, gout).
  • History of chronic pain (eg, fibromyalgia), metastasis, and Paget's disease.
  • History of alcohol or drug abuse in the last year according to DSM-V.
  • Clinical and radiological data of cervical sprain grade III or IV of the Quebec scale.
  • History of illness or injury for more than 6 months in the neck or cervical spine
  • Patient with symptoms of spinal cord injury (weakness, incoordination or paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, etc.)
  • History of severe acute or chronic liver failure.
  • History of moderate to severe renal failure.
  • A significant history of coagulation problems (Von Willembrand, hemophilia, vitamin K deficiency, etc.).
  • At medical discretion, a disease that affects the prognosis and prevents outpatient management, for example, but not restricted to: end-stage cancer, kidney, heart, respiratory or liver failure or mental illness or with scheduled surgical or hospital procedures.
  • History / presence of any disease or condition that, in the opinion of the Investigator, could pose a risk to the patient or confuse the efficacy and safety of the study results.
  • Oncological patients (except basal cell skin cancer) or with serious diseases that, in the opinion of the investigator, have a serious prognosis or a life expectancy of less than 1 year, as well as mental illnesses.
  • Patients with symptoms suggesting an active COVID-19 infection (ie, fever, cough, dyspnea) and / or contact in the past 14 days with a suspected or positive COVID-19 patient.
  • Patient is participating in another clinical study involving an investigational treatment or participated in one in the previous 4 weeks.
  • Patients whose participation in the study may be influenced (employment relationship with the research center or sponsor, inmates, etc.)
  • Positive pregnancy test, women who are pregnant, breastfeeding or planning a pregnancy while conducting the study.

Sites / Locations

  • Laboratorio Silanes, S.A. de C.V.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)

Group B: Dexketoprofen

Arm Description

Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days.

Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.

Outcomes

Primary Outcome Measures

Changes in pain intensity
Compare changes in pain intensity measured by the visual analog scale (VAS) between treatment groups. The VAS for pain is a straight line of 10 centimeters in which one end means no pain and the other end means the worst pain imaginable.
Change in the degree of disability
Compare the degree of disability due to neck pain measured through the Northwick Park Neck Pain Questionnaire Spanish version between the treatment groups. It includes 9 questions or items (intensity of neck pain, and sleep, pins and needles in the arms at night, duration of symptoms, lifting weights, reading and watching TV, work, social activities and driving). Each of these questions has five possible answers with a score of 0 to 4, from less to greater intensity and severity respectively.
Proportion of subjects requiring rescue medication
Compare the proportion of subjects requiring rescue medication during the study between treatment groups.
Adverse events frequency
Compare the proportion of subjects that presented an adverse event between treatment groups.
Adverse events intensity
Compare the intensity of adverse events presented during the study, between treatment groups.

Secondary Outcome Measures

Full Information

First Posted
July 29, 2021
Last Updated
June 12, 2023
Sponsor
Laboratorios Silanes S.A. de C.V.
search

1. Study Identification

Unique Protocol Identification Number
NCT05001555
Brief Title
Efficacy and Safety of Dexketoprofen/Vitamin B vs Dexketoprofen for Post-traumatic Cervical Sprain Grade I-II
Acronym
WHIPLASH
Official Title
Efficacy and Safety of the Combination Dexketoprofen / Vitamin B vs Dexketoprofen in the Treatment of Pain in Patients With Post-traumatic Cervical Sprain Grade I-II of the Quebec Scale.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Completed
Study Start Date
November 23, 2021 (Actual)
Primary Completion Date
April 24, 2023 (Actual)
Study Completion Date
April 25, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Laboratorios Silanes S.A. de C.V.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Phase IIIb, multicenter, prospective, randomized, double-blind study to evaluate the fixed combination of Desketoprofen / Vitamin B in the management of acute pain in patients with cervical sprain grade I-II of the Quebec scale.
Detailed Description
Study to evaluate the efficacy and safety of the Dexketoprofen / Vitamin B combination versus dexketoprofen for the management of acute pain secondary to post-traumatic cervical sprain grade I-II of the Quebec scale, evaluated by means of the Visual Analogue Scale (VAS). To compare the degree of disability due to neck pain measured through the Northwick Park Neck Pain Questionnaire in Spanish version on days 3, 5, and 7 compare to its baseline measurement between the treatment groups. Compare the proportion of subjects requiring rescue medication during the study between treatment groups. Describe the frequency and intensity of adverse events presented during the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Low Back Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
174 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin)
Arm Type
Experimental
Arm Description
Group A: Dexketoprofen/Vitamin B (Thiamine mononitrate/Pyridoxine hydrochloride/Cyanocobalamin), 1 capsule, orally, every 8 hours, for 7 days.
Arm Title
Group B: Dexketoprofen
Arm Type
Active Comparator
Arm Description
Group B: Dexketoprofen, 1 tablet, orally, every 8 hours, for 7 days.
Intervention Type
Drug
Intervention Name(s)
Dexketoprofen/Vitamin B
Other Intervention Name(s)
D/VitB
Intervention Description
1 capsule containing 25 mg of dexketoprofen / vitamin B (thiamine mononitrate 100 mg, Pyridoxine hydrochloride 50 mg, Cyanocobalamin 0.50 mg), orally, every 8 hours, for 7 days.
Intervention Type
Drug
Intervention Name(s)
Dexketoprofen
Other Intervention Name(s)
D
Intervention Description
1 tablet of dexketoprofen 25 mg, orally, every 8 hours, for 7 days.
Primary Outcome Measure Information:
Title
Changes in pain intensity
Description
Compare changes in pain intensity measured by the visual analog scale (VAS) between treatment groups. The VAS for pain is a straight line of 10 centimeters in which one end means no pain and the other end means the worst pain imaginable.
Time Frame
Baseline, 3, 5 and 7 days
Title
Change in the degree of disability
Description
Compare the degree of disability due to neck pain measured through the Northwick Park Neck Pain Questionnaire Spanish version between the treatment groups. It includes 9 questions or items (intensity of neck pain, and sleep, pins and needles in the arms at night, duration of symptoms, lifting weights, reading and watching TV, work, social activities and driving). Each of these questions has five possible answers with a score of 0 to 4, from less to greater intensity and severity respectively.
Time Frame
Baseline, 3, 5 and 7 days
Title
Proportion of subjects requiring rescue medication
Description
Compare the proportion of subjects requiring rescue medication during the study between treatment groups.
Time Frame
7 days
Title
Adverse events frequency
Description
Compare the proportion of subjects that presented an adverse event between treatment groups.
Time Frame
7 days
Title
Adverse events intensity
Description
Compare the intensity of adverse events presented during the study, between treatment groups.
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Any sex. That the subject agree to participate in the study and give your written informed consent. Age> 18 years old at the beginning of the study. Diagnosis of a grade I or Grade II cervical sprain on the Quebec scale of no more than 3 days. Visual Analog Scale (VAS) ≥4 cm. Women of childbearing potential using a contraceptive method (barrier, oral hormonal, injectable, subdermal), menopausal or surgically sterile. Exclusion Criteria: Patient in whom the drug is contraindicated for medical reasons. History of allergic reaction to NSAIDs, thiamine, pyridoxine and cyanocobalamin or hypersensitivity to the components of the formula. A significant history of gastrointestinal disorders (for example: Gastric Ulcer, Crohn's Disease, Ulcerative Colitis, etc.) Previous treatment with opioids reported in the medical history. History of inflammatory arthritis (eg rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, gout). History of chronic pain (eg, fibromyalgia), metastasis, and Paget's disease. History of alcohol or drug abuse in the last year according to DSM-V. Clinical and radiological data of cervical sprain grade III or IV of the Quebec scale. History of illness or injury for more than 6 months in the neck or cervical spine Patient with symptoms of spinal cord injury (weakness, incoordination or paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, etc.) History of severe acute or chronic liver failure. History of moderate to severe renal failure. A significant history of coagulation problems (Von Willembrand, hemophilia, vitamin K deficiency, etc.). At medical discretion, a disease that affects the prognosis and prevents outpatient management, for example, but not restricted to: end-stage cancer, kidney, heart, respiratory or liver failure or mental illness or with scheduled surgical or hospital procedures. History / presence of any disease or condition that, in the opinion of the Investigator, could pose a risk to the patient or confuse the efficacy and safety of the study results. Oncological patients (except basal cell skin cancer) or with serious diseases that, in the opinion of the investigator, have a serious prognosis or a life expectancy of less than 1 year, as well as mental illnesses. Patients with symptoms suggesting an active COVID-19 infection (ie, fever, cough, dyspnea) and / or contact in the past 14 days with a suspected or positive COVID-19 patient. Patient is participating in another clinical study involving an investigational treatment or participated in one in the previous 4 weeks. Patients whose participation in the study may be influenced (employment relationship with the research center or sponsor, inmates, etc.) Positive pregnancy test, women who are pregnant, breastfeeding or planning a pregnancy while conducting the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Miguel A Zurqui Ramírez, M.D
Organizational Affiliation
Icaro Investigación en Medicina S.A. de C.V.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Adelfia Urenda Quezada, M.D
Organizational Affiliation
Mediadvance Clinical S.A.P.I. de C.V.
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ma. Dolores Alonso Martínez, M.D
Organizational Affiliation
CICMEX Centro de Investigación Clínica de México
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Juan B Alcocer Herrera, M.D
Organizational Affiliation
INBIOMEDyC Querétaro
Official's Role
Principal Investigator
Facility Information:
Facility Name
Laboratorio Silanes, S.A. de C.V.
City
Mexico City
ZIP/Postal Code
11000
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
7604354
Citation
Spitzer WO, Skovron ML, Salmi LR, Cassidy JD, Duranceau J, Suissa S, Zeiss E. Scientific monograph of the Quebec Task Force on Whiplash-Associated Disorders: redefining "whiplash" and its management. Spine (Phila Pa 1976). 1995 Apr 15;20(8 Suppl):1S-73S. No abstract available. Erratum In: Spine 1995 Nov 1;20(21):2372.
Results Reference
background
PubMed Identifier
15170609
Citation
Rodriquez AA, Barr KP, Burns SP. Whiplash: pathophysiology, diagnosis, treatment, and prognosis. Muscle Nerve. 2004 Jun;29(6):768-81. doi: 10.1002/mus.20060.
Results Reference
background
PubMed Identifier
11148643
Citation
Hartling L, Brison RJ, Ardern C, Pickett W. Prognostic value of the Quebec Classification of Whiplash-Associated Disorders. Spine (Phila Pa 1976). 2001 Jan 1;26(1):36-41. doi: 10.1097/00007632-200101010-00008.
Results Reference
background
PubMed Identifier
29023870
Citation
Bagan JV, Lopez Arranz JS, Valencia E, Santamaria J, Eguidazu I, Horas M, Forns M, Zapata A, Artigas R, Mauleon D. Clinical Comparison of Dexketoprofen Trometamol and Dipyrone in Postoperative Dental Pain. J Clin Pharmacol. 1998 Dec;38(S1):55S-64S. doi: 10.1002/jcph.1998.38.s1.55.
Results Reference
background
PubMed Identifier
22135737
Citation
Ponce-Monter HA, Ortiz MI, Garza-Hernandez AF, Monroy-Maya R, Soto-Rios M, Carrillo-Alarcon L, Reyes-Garcia G, Fernandez-Martinez E. Effect of diclofenac with B vitamins on the treatment of acute pain originated by lower-limb fracture and surgery. Pain Res Treat. 2012;2012:104782. doi: 10.1155/2012/104782. Epub 2011 Oct 31.
Results Reference
background
PubMed Identifier
12516888
Citation
Curatolo M, Sveticic G. Drug combinations in pain treatment: a review of the published evidence and a method for finding the optimal combination. Best Pract Res Clin Anaesthesiol. 2002 Dec;16(4):507-19. doi: 10.1053/bean.2002.0254.
Results Reference
background
PubMed Identifier
20037567
Citation
Levin OS, Moseikin IA. [Vitamin B complex (milgamma) in the treatment of vertebrogenic lumbosacral radiculopathy]. Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(10):30-5. Russian.
Results Reference
background
PubMed Identifier
2138683
Citation
Kuhlwein A, Meyer HJ, Koehler CO. [Reduced diclofenac administration by B vitamins: results of a randomized double-blind study with reduced daily doses of diclofenac (75 mg diclofenac versus 75 mg diclofenac plus B vitamins) in acute lumbar vertebral syndromes]. Klin Wochenschr. 1990 Jan 19;68(2):107-15. doi: 10.1007/BF01646857. German.
Results Reference
background
PubMed Identifier
14699896
Citation
Perez-Flores E, Medina-Santillan R, Reyes-Garcia G, Mateos-Garcia E. Combination of diclofenac plus B vitamins in acute pain after tonsillectomy: a pilot study. Proc West Pharmacol Soc. 2003;46:88-90. No abstract available.
Results Reference
background
PubMed Identifier
19731994
Citation
Mibielli MA, Geller M, Cohen JC, Goldberg SG, Cohen MT, Nunes CP, Oliveira LB, da Fonseca AS. Diclofenac plus B vitamins versus diclofenac monotherapy in lumbago: the DOLOR study. Curr Med Res Opin. 2009 Nov;25(11):2589-99. doi: 10.3111/13696990903246911.
Results Reference
background
PubMed Identifier
11247324
Citation
Gonzalez T, Balsa A, Sainz de Murieta J, Zamorano E, Gonzalez I, Martin-Mola E. Spanish version of the Northwick Park Neck Pain Questionnaire: reliability and validity. Clin Exp Rheumatol. 2001 Jan-Feb;19(1):41-6.
Results Reference
background
PubMed Identifier
28540716
Citation
Gaskell H, Derry S, Wiffen PJ, Moore RA. Single dose oral ketoprofen or dexketoprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2017 May 25;5(5):CD007355. doi: 10.1002/14651858.CD007355.pub3.
Results Reference
background

Learn more about this trial

Efficacy and Safety of Dexketoprofen/Vitamin B vs Dexketoprofen for Post-traumatic Cervical Sprain Grade I-II

We'll reach out to this number within 24 hrs